Research Abstract
1. Develop more effective therapies for hepatocellular carcinoma and cholangiocarcinoma through phase I, II and III clinical trials.
2. Identify novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance.
3. Define and characterize known or novel genetic mutations in hepatocellular carcinoma and cholangiocarcinoma, and assess their potential correlation with clinical outcomes and as therapeutic targets.
4. Dissect the molecular mechanism of drug resistance to targeted therapy in hepatobiliary cancers.